Systematic reviews and meta-analyses of randomized trials: principles and pitfalls

Systematic reviews and meta-analyses allow for a more transparent and objective appraisal of the evidence. They may decrease the number of false-negative results and prevent delays in the introduction of effective interventions into clinical practice. However, as for any other tool, their misuse can result in severely misleading results. In this article, we discuss the main steps that should be taken when conducting systematic reviews and meta-analyses, namely the preparation of a review protocol, identification of eligible trials, and data extraction, pooling of treatment effects across trials, investigation of potential reasons for differences in treatment effects across trials, and complete reporting of the review methods and findings. We also discuss common pitfalls that should be avoided, including the use of quality assessment tools to derive summary quality scores, pooling of data across trials as if they belonged to a single large trial, and inappropriate uses of meta-regression that could result in misleading estimates of treatment effects because of regression to the mean or the ecological fallacy. If conducted and reported properly, systematic reviews and meta-analyses will increase our understanding of the strengths and weaknesses of the available evidence, which may eventually facilitate clinical decision making.

[1]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration , 2009, BMJ : British Medical Journal.

[2]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[3]  D. Moher,et al.  PROSPERO at one year: an evaluation of its utility , 2013, Systematic Reviews.

[4]  Douglas G Altman,et al.  Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study , 2008, BMJ : British Medical Journal.

[5]  S. Nashef,et al.  The logistic EuroSCORE , 2003 .

[6]  S Greenland,et al.  On the bias produced by quality scores in meta-analysis, and a hierarchical view of proposed solutions. , 2001, Biostatistics.

[7]  Douglas G Altman,et al.  Systematic reviews in health care: Assessing the quality of controlled clinical trials. , 2001, BMJ.

[8]  G. Guyatt,et al.  GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). , 2011, Journal of clinical epidemiology.

[9]  M. Egger,et al.  The hazards of scoring the quality of clinical trials for meta-analysis. , 1999, JAMA.

[10]  George Davey Smith,et al.  Meta-analysis: Principles and procedures , 1997, BMJ.

[11]  Cynthia D Mulrow,et al.  Random-Effects Meta-analysis of Inconsistent Effects: A Time for Change , 2014, Annals of Internal Medicine.

[12]  S. Greenland Quality Scores Are Useless and Potentially Misleading: Reply to “Re: A Critical Look at Some Popular Analytic Methods” , 1994 .

[13]  Douglas G Altman,et al.  Meta-analysis, Simpson's paradox, and the number needed to treat , 2002, BMC medical research methodology.

[14]  Douglas G Altman,et al.  Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study , 2010, BMJ : British Medical Journal.

[15]  S. Senn,et al.  IMPORTANCE OF TRENDS IN THE INTERPRETATION OF AN OVERALL ODDS RATIO IN THEMETA-ANALYSIS OF CLINICAL TRIALS. AUTHOR'S REPLY , 1994 .

[16]  Gerta Rücker,et al.  Bmc Medical Research Methodology Open Access Undue Reliance on I 2 in Assessing Heterogeneity May Mislead , 2022 .

[17]  S. Bagshaw,et al.  Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: A systematic review and meta-analysis , 2004, BMC medicine.

[18]  黄亚明(整理),et al.  Equator network , 2012 .

[19]  H Kragt,et al.  Importance of trends in the interpretation of an overall odds ratio in the meta-analysis of clinical trials. , 1992, Statistics in medicine.

[20]  Peter Jüni,et al.  Commentary: Which meta-analyses are conclusive? , 2009, International journal of epidemiology.

[21]  R. J. Hayes,et al.  Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.

[22]  G. Smith,et al.  Meta-analysis: Potentials and promise , 1997, BMJ.

[23]  R. Riley,et al.  Meta-analysis of individual participant data: rationale, conduct, and reporting , 2010, BMJ : British Medical Journal.

[24]  David Moher,et al.  Forest plots in reports of systematic reviews: a cross-sectional study reviewing current practice. , 2010, International journal of epidemiology.

[25]  S G Thompson,et al.  Systematic Review: Why sources of heterogeneity in meta-analysis should be investigated , 1994, BMJ.

[26]  Jonathan J Deeks,et al.  Issues in the selection of a summary statistic for meta‐analysis of clinical trials with binary outcomes , 2002, Statistics in medicine.

[27]  L. Smeeth,et al.  Numbers needed to treat derived from meta-analyses—sometimes informative, usually misleading , 1999, BMJ.

[28]  Douglas G Altman,et al.  The relation between treatment benefit and underlying risk in meta-analysis , 1996, BMJ.

[29]  M. Egger,et al.  PEDro's bias: summary quality scores should not be used in meta-analysis. , 2013, Journal of clinical epidemiology.

[30]  Raymond C. Schneider,et al.  ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction , 1995, The Lancet.

[31]  J. Tierney Chapter 18: Reviews of individual patient data , 2008 .

[32]  M. Egger,et al.  Circumcision in men and the prevention of HIV infection: a 'meta-analysis' revisited , 2000, International journal of STD & AIDS.

[33]  M. Egger,et al.  PRISMAtic reporting of systematic reviews and meta-analyses , 2009, The Lancet.

[34]  R. Heller,et al.  14. Modern methods of searching the medical literature , 1992 .

[35]  D. Altman,et al.  The importance of allocation concealment and patient blinding in osteoarthritis trials: a meta-epidemiologic study. , 2009, Arthritis and rheumatism.

[36]  Marco Valgimigli,et al.  Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. , 2012, European heart journal.

[37]  A. Qaseem,et al.  Prospective systematic review registration: perspective from the Guidelines International Network (G-I-N) , 2012, Systematic Reviews.

[38]  J. Glanville,et al.  Searching for Studies , 2008 .

[39]  S. Thompson,et al.  How should meta‐regression analyses be undertaken and interpreted? , 2002, Statistics in medicine.

[40]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[41]  Harold I Feldman,et al.  Individual patient‐ versus group‐level data meta‐regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head , 2002, Statistics in medicine.

[42]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[43]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[44]  Roger M Harbord,et al.  A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpoints , 2006, Statistics in medicine.

[45]  D. Altman,et al.  Statistics Notes: Some examples of regression towards the mean , 1994 .